Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.

Parameter adaptations during phenotype transitions in progressive diseases

Open access
Tiemann, Christian A, Vanlier, Joep, Hilbers, Peter AJ, van Riel, Natal AW · 2011 · BMC Systems Biology

Abstract

BACKGROUND: The study of phenotype transitions is important to understand progressive diseases, e.g., diabetes mellitus, metabolic syndrome, and cardiovascular diseases. A challenge remains to explain phenotype transitions in terms of adaptations in molecular components and interactions in underlying biological systems. RESULTS: Here, mathematical modeling is used to describe the different phenotypes by integrating experimental data on metabolic pools and fluxes. Subsequently, trajectories of parameter adaptations are identified that are essential for the phenotypical changes. These changes in parameters reflect progressive adaptations at the transcriptome and proteome level, which occur at larger timescales. The approach was employed to study the metabolic processes underlying liver X receptor induced hepatic steatosis. Model analysis predicts which molecular processes adapt in time after pharmacological activation of the liver X receptor. Our results show that hepatic triglyceride fluxes are increased and triglycerides are especially stored in cytosolic fractions, rather than in endoplasmic reticulum fractions. Furthermore, the model reveals several possible scenarios for adaptations in cholesterol metabolism. According to the analysis, the additional quantification of one cholesterol flux is sufficient to exclude many of these hypotheses. CONCLUSIONS: We propose a generic computational approach to analyze biological systems evolving through various phenotypes and to predict which molecular processes are responsible for the transition. For the case of liver X receptor induced hepatic steatosis the novel approach yields information about the redistribution of fluxes and pools of triglycerides and cholesterols that was not directly apparent from the experimental data. Model analysis provides guidance which specific molecular processes to study in more detail to obtain further understanding of the underlying biological system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1752-0509-5-174

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Hepatic lipid and plasma lipoprotein metabolism. The mathematical model has three compartments representing the liver, blood plasma, and peripheral tissues. The liver compartment includes reactions representing the production, utilization and storage of triglycerides and cholesterols, and the mobilization of these metabolites to the endoplasmic reticulum, where they are incorporated into nascent produced VLDL particles. The VLDL particles are secreted in the plasma compartment where they serve as nutrients for peripheral tissues. Remnant particles are taken up and cleared by the liver. The model furthermore includes the hepatic uptake of free fatty acids and reverse cholesterol transport via HDL. ABCA1, ATP-binding cassette transporter 1; ACAT, acyl-CoA: cholesterol acyltransferase; ApoB, apolipoprotein B; CE, cholesterylester; DGAT, diglyceride acyltransferase; ER, endoplasmic reticulum; FFA, free fatty acid; FC, free cholesterol; HDL, high-density-lipoprotein; HSL, hormone-sensitive lipase; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; LDLr, low density lipoprotein receptor; LPL, lipoprotein lipase; MTP, microsomal triglyceride transfer protein; SR-B1, scavenger receptor class B1; TG, triglyceride; TGH, triglyceride hydrolase; VLDL, very low density lipoprotein; VLDLr, very low density lipoprotein receptor.
Figure 1 Hepatic lipid and plasma lipoprotein metabolism. The mathematical model has three compartments representing the liver, blood plasma, and peripheral tissues. The liver compartment includes reactions representing the production, utilization and storage of triglycerides and cholesterols, and the mobilization of these metabolites to the endoplasmic reticulum, where they are incorporated into nascent produced VLDL particles. The VLDL particles are secreted in the plasma compartment where they serve as nutrients for peripheral tissues. Remnant particles are taken up and cleared by the liver. The model furthermore includes the hepatic uptake of free fatty acids and reverse cholesterol transport via HDL. ABCA1, ATP-binding cassette transporter 1; ACAT, acyl-CoA: cholesterol acyltransferase; ApoB, apolipoprotein B; CE, cholesterylester; DGAT, diglyceride acyltransferase; ER, endoplasmic reticulum; FFA, free fatty acid; FC, free cholesterol; HDL, high-density-lipoprotein; HSL, hormone-sensitive lipase; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; LDLr, low density lipoprotein receptor; LPL, lipoprotein lipase; MTP, microsomal triglyceride transfer protein; SR-B1, scavenger receptor class B1; TG, triglyceride; TGH, triglyceride hydrolase; VLDL, very low density lipoprotein; VLDLr, very low density lipoprotein receptor.CC BY · PubMed Central
Figure 2 Parameter scatter plots and predictions. Several parameters are very constrained by the data and have a well defined value (A and B), whereas others show a larger spread of possible values (D and E). The black dots represent the 108 initial sampled parameter values (individual dots not visible), whereas the red dots represent the 104 best parameter sets which were optimized. The resulting 2909 acceptable parameter sets that describe the experimental data are shown in green. Model predictions for the depositioning of hepatic triglycerides (C) and cholesterylesters (F) in cytoplasmic and endoplasmic reticulum fractions were obtained for all acceptable parameter sets. Note that only the total pools of triglyceride and cholesterylester were measured. The predictions for the triglyceride fractions are consistent, whereas the predictions for the cholesterylester fractions show a larger spread of possible outcomes.
Figure 2 Parameter scatter plots and predictions. Several parameters are very constrained by the data and have a well defined value (A and B), whereas others show a larger spread of possible values (D and E). The black dots represent the 108 initial sampled parameter values (individual dots not visible), whereas the red dots represent the 104 best parameter sets which were optimized. The resulting 2909 acceptable parameter sets that describe the experimental data are shown in green. Model predictions for the depositioning of hepatic triglycerides (C) and cholesterylesters (F) in cytoplasmic and endoplasmic reticulum fractions were obtained for all acceptable parameter sets. Note that only the total pools of triglyceride and cholesterylester were measured. The predictions for the triglyceride fractions are consistent, whereas the predictions for the cholesterylester fractions show a larger spread of possible outcomes.CC BY · PubMed Central
Figure 3 Single-step versus multi-step optimization. A) An example of an acceptable parameter set describing the wild-type phenotype, which was not successfully optimized by single-step optimization to describe the LXR activated phenotype. This problem was circumvented by multi-step optimization. In the latter case, the parameter estimation is carried out in a step-wise fashion. Hereto, the experimental data is interpolated from the wild-type phenotype to the LXR activated phenotype. At each interpolation step the parameters are reoptimized in order to describe the newly interpolated data. This procedure is repeated until the final state representing phenotype B is reached. B, C) Two examples of corresponding parameter trajectories from the wild-type phenotype to the LXR activated phenotype, normalized by the initial parameters of the wild-type phenotype.
Figure 3 Single-step versus multi-step optimization. A) An example of an acceptable parameter set describing the wild-type phenotype, which was not successfully optimized by single-step optimization to describe the LXR activated phenotype. This problem was circumvented by multi-step optimization. In the latter case, the parameter estimation is carried out in a step-wise fashion. Hereto, the experimental data is interpolated from the wild-type phenotype to the LXR activated phenotype. At each interpolation step the parameters are reoptimized in order to describe the newly interpolated data. This procedure is repeated until the final state representing phenotype B is reached. B, C) Two examples of corresponding parameter trajectories from the wild-type phenotype to the LXR activated phenotype, normalized by the initial parameters of the wild-type phenotype.CC BY · PubMed Central
Figure 4 Effect of regularization strength. A) Model error Xd for all acceptable parameter sets for increasing λ, where green indicates an acceptable data fit and red an unacceptable data fit. B) Regularization error Xr for increasing λ. Note that a small λ is already sufficient to minimize parameter changes, while describing the experimental data still very well. A λ of 0.1 was selected (dashed line).
Figure 4 Effect of regularization strength. A) Model error Xd for all acceptable parameter sets for increasing λ, where green indicates an acceptable data fit and red an unacceptable data fit. B) Regularization error Xr for increasing λ. Note that a small λ is already sufficient to minimize parameter changes, while describing the experimental data still very well. A λ of 0.1 was selected (dashed line).CC BY · PubMed Central
Figure 5 Regularization of parameter trajectories. Three examples of parameter trajectories from the wild-type phenotype to the LXR activated phenotype obtained without regularization (blue dashed) and with regularization using λ = 0.1 (red).
Figure 5 Regularization of parameter trajectories. Three examples of parameter trajectories from the wild-type phenotype to the LXR activated phenotype obtained without regularization (blue dashed) and with regularization using λ = 0.1 (red).CC BY · PubMed Central
Figure 6 (In)consistency of parameter adaptation trajectories. Three examples of back and forward parameter trajectories from the wild-type phenotype to the LXR activated phenotype, using a hundred repetitions.
Figure 6 (In)consistency of parameter adaptation trajectories. Three examples of back and forward parameter trajectories from the wild-type phenotype to the LXR activated phenotype, using a hundred repetitions.CC BY · PubMed Central
Figure 7 Flux adaptations upon T0901317 induced LXR activation. Flux trajectories from the wild-type phenotype (green) to the LXR activated phenotype (red). The data interpolation was carried out in a hundred steps and the back and forward flux trajectories were determined using a hundred repetitions. Molecular fluxes (A-C, E-H) are given in mM/h, whereas the triglyceride concentrations presented in (D) are given in mM.
Figure 7 Flux adaptations upon T0901317 induced LXR activation. Flux trajectories from the wild-type phenotype (green) to the LXR activated phenotype (red). The data interpolation was carried out in a hundred steps and the back and forward flux trajectories were determined using a hundred repetitions. Molecular fluxes (A-C, E-H) are given in mM/h, whereas the triglyceride concentrations presented in (D) are given in mM.CC BY · PubMed Central
Figure 8 Adaptations in cholesterol metabolism upon T0901317 induced LXR activation. Adaptations in metabolic processes/components involved in hepatic cholesterol metabolism, normalized by the values of corresponding wild-type phenotype. The green dots represent the wild-type phenotype, whereas the blue and black dots represent the LXR activated phenotype. Solutions corresponding to an increased HDL-CE synthesis/uptake rate are colored blue, whereas solutions corresponding to a decreased HDL-CE synthesis/uptake rate are colored black. The ellipses were calculated by means of principal component analysis (PCA) and contain 95% of the corresponding solutions. ABCA1, ATP-binding cassette transporter 1; ABCG5, ATP-binding cassette transporter G5; SR-B1, scavenger receptor class B1.
Figure 8 Adaptations in cholesterol metabolism upon T0901317 induced LXR activation. Adaptations in metabolic processes/components involved in hepatic cholesterol metabolism, normalized by the values of corresponding wild-type phenotype. The green dots represent the wild-type phenotype, whereas the blue and black dots represent the LXR activated phenotype. Solutions corresponding to an increased HDL-CE synthesis/uptake rate are colored blue, whereas solutions corresponding to a decreased HDL-CE synthesis/uptake rate are colored black. The ellipses were calculated by means of principal component analysis (PCA) and contain 95% of the corresponding solutions. ABCA1, ATP-binding cassette transporter 1; ABCG5, ATP-binding cassette transporter G5; SR-B1, scavenger receptor class B1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 22

Metadata

Authors
Tiemann, C. A., Vanlier, J., Hilbers, P. A., & van Riel, N. A.
Affiliations
Eindhoven University of Technology (NL)
Corresponding author
Tiemann, Christian A
Venue
BMC Systems Biology
Published
2011
Volume
5
Issue
1
Pages
174
ISSN
1752-0509 (ISSN-L)
OpenAlex
W1999787554
Cited by
22
References
66
Citations by year
2022: 2 · 2021: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 4
FWCI
1.30
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Systems Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • TU/e Research Portal (publishedVersion, other-oa)
  • TU/e Research Portal (submittedVersion)
  • TU/e Research Portal (submittedVersion, other-oa)
Funders
Universiteit van Amsterdam
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Microbial Metabolic Engineering and Bioproduction
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
phenotype transition, progressive disease, parameter adaptation, metabolic flux analysis, liver X receptor, hepatic steatosis, triglyceride metabolism, cholesterol metabolism, metabolic pools, metabolic modeling
MeSH terms
Liver X Receptors, Animals, Computer Simulation, Fatty Liver, Mice, Inbred C57BL, Models, Biological, Phenotype, Computational Biology, Systems Biology, Mice, Metabolic Networks and Pathways, Orphan Nuclear Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Parameter adaptations during phenotype transitions in progressive diseases. https://app.cochat.ai/papers/10.1186/1752-0509-5-174
The paper
Tiemann, C. A., Vanlier, J., Hilbers, P. A., & van Riel, N. A. (2011). Parameter adaptations during phenotype transitions in progressive diseases. BMC Systems Biology. https://doi.org/10.1186/1752-0509-5-174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.